beta
Trial Radar AI
Clinical Trial NCT07489417 for Sleep, Blood Pressure is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Impact of Sleep Restriction on Blood Pressure Reactivity 45

Recruiting
Clinical Trial NCT07489417 is an interventional study for Sleep, Blood Pressure that is recruiting. It started on 4 March 2026 with plans to enroll 45 participants. Led by University of Missouri-Columbia, it is expected to complete by 1 August 2027. The latest data from ClinicalTrials.gov was last updated on 24 March 2026.
Brief Summary
The purpose of the research study is to examine the effects of shortened sleep on blood pressure.
Official Title

Impact of Sleep Restriction on Blood Pressure Reactivity

Conditions
SleepBlood Pressure
Other Study IDs
  • 2132616
NCT ID Number
NCT07489417
Start Date (Actual)
2026-03-04
Last Update Posted
2026-03-24
Completion Date (Estimated)
2027-08
Enrollment (Estimated)
45
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Keywords
Sleep
Blood pressure
Primary Purpose
Basic Science
Design Allocation
Non-Randomized
Interventional Model
Crossover Assignment
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalSleep Restriction
You will be asked to shorten your sleep to four hours.
Sleep Restriction
You will be asked to shorten your sleep to four hours.
No InterventionNormal Sleep
You will be asked to sleep for 7-9 hours.
N/A
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Blood Pressure
Blood pressure
Baseline and during the last 1-minute of stress
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult
Minimum Age
18 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes
  • Healthy adult men and women
  • 18-45 years of age
  • BMI < 25 kg/m² (normal weight group) or ≥ 30 kg/m² (obesity group)
  • Non-pregnant, non-breastfeeding, and non-nicotine users
  • Self-reported history of normal sleep duration (7-9 hours/night) and bedtime prior to midnight
  • Premenopausal

  • No acute or chronic conditions
  • Taking no medications known to affect sleep, autonomic, metabolic, or cardiovascular function
  • Self-reported history of irregular sleep
  • Self-reported history of hepatic, renal, pulmonary, cardiovascular, or neurological disease, stroke or neurovascular disease, bleeding/clotting disorders, sleep apnea or other sleep disorders, diabetes, history of alcoholism or substance abuse, major cardiovascular event or surgical procedure within the past three months, or hypertension
University of Missouri-Columbia logoUniversity of Missouri-Columbia94 active studies to explore
Study Responsible Party
Jacqueline K Limberg, PhD, Principal Investigator, Associate Professor, University of Missouri-Columbia
Study Central Contact
Contact: Jacqueline Limberg, 1-573-882-2544, [email protected]
1 Study Locations in 1 Countries

Missouri

University of Missouri, Columbia, Missouri, 65211, United States
Jacqueline Limberg, Contact, 573-882-2544, [email protected]
Jacqueline Limberg, Principal Investigator
Recruiting